Navigation Links
Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Date:1/22/2013

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T-cells", authored by Henle et al, J.Immunol. (2013), 190, 479-488.  This work, performed in the laboratory of Dr Keith Knutson at Mayo Clinic, describes the discovery of a novel HER-2/neu Class I epitope (p373-382) TapImmune has licensed from Mayo Clinic for the development of breast cancer vaccines.  The significance of this work is that this newly discovered antigen is a naturally occurring antigen processed by the proteasome and elicits peptide-specific T-cell responses.  This results in stronger binding to HLA-A2 and more efficient killing of HER-2/neu positive breast cancer cells by activated T-cells compared to the Class I epitope, p369-377 (E75) which was not naturally processed by the proteasome.

"These results provide an explanation of the molecular immunology behind our approach to HER-2/neu immunotherapy," said Mark Reddish Vice President of TapImmune Inc.  "These data describe how the HER-2/neu protein is processed by the proteasome to then be presented for immune recognition and killing.  By revealing the true identity of the immunodominant epitope responsible for class I mediated killing of HER-2/neu positive tumors, it is now possible to generate a true second generation vaccine that incorporates the correct target as it naturally appears on human tumors.  For nearly 20 years the immunology of this key protein has been clouded by contradictory observations, and these data finally provide an understanding of the 'natural target' displayed on human tumors. We expect to combine this immunodominant peptide with our broadly reactive helper peptides that are currently being tested in a phase I trial, to create a tru
'/>"/>

SOURCE TapImmune Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Report Details NCPA Efforts to Drive Greater Medication Adherence
2. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
3. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
4. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
5. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
6. Physician Details Problems with Medicare Approval Process for Power Wheelchairs
7. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
8. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
9. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
10. Barrack, Rodos & Bacine Files Class Action Lawsuit Against St. Jude Medical, Inc.
11. Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ANTONIO , Jan. 15, 2014 Most osteoporosis ... according to a recent online survey* sponsored by Mission ... among the National Osteoporosis Foundation online support community, revealed ... take medication that comes in a form other than ...
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... 2011 Stereotaxis, Inc. (NASDAQ: STXS ) today ... Healthcare Conference to be held September 27-28, 2011 in New ... of Stereotaxis, is scheduled to present an overview of the ... A live webcast and subsequent archived replay ...
... PRINCETON, N.J., Sept. 15, 2011 Soligenix, Inc. ... biopharmaceutical company, announced that an independent Data Safety ... analysis for safety and futility for Soligenix,s confirmatory ... formulation of beclomethasone dipropionate (BDP) in acute gastrointestinal ...
Cached Medicine Technology:Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011 2Stereotaxis to Present at the JMP Securities Healthcare Conference on September 28, 2011 3Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 2Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 3Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 4Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 5Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 6
(Date:4/23/2014)... predict which patients might suffer potentially fatal side-effects from ... assesses brain scans using pattern recognition software similar to ... been developed by researchers at Imperial College London. Results ... which used the software are published in the journal ... 15 million people each year worldwide. Ischemic strokes are ...
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... SEATTLE, Washington, April 21, 2014 Five for-profit ... total of $1.25 million in Proof of Concept ... from ideas into commercial products, the Life Sciences ... a $300,000 Entrepreneur Mentoring Program grant to the ... a statewide advisory network to train the next ...
(Date:4/23/2014)... Effects of Midlife Occupational and Leisure Time Physical Activity ... physical activity in midlife increases the risk of mobility ... the risk. This is found in a study which ... The study was conducted at the Gerontology Research Center ... , Heavy physical labor is often repetitive, wears the ...
(Date:4/23/2014)... shown that proliferation of endogenous neural precursor cells ... and axons. From the perspective of neural plasticity, ... University in China observed the effects of functional ... proliferation and expression of basic fibroblast growth factor ... on the infarct side. The researchers found that ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... of bird flu which had reached a feverish pitch early in ... //if the virus has actually beaten a retreat. , ... flu is dynamic in the winter months, as the virus can ... The H5N1 virus which had earlier restricted itself to Southeast Asia ...
... the University of North Carolina at Chapel Hill School of ... according to a study by an international group of researchers. ... by Dr. Carol Otey and her former student, Dr. Mana ... in Boston. Otey has shown that palladin is involved in ...
... basic symptoms associated with ovarian cancer may aid clinicians ... a new study.// This index is expected to serve ... details of this study is published in the January ... of the American Cancer Society, the study reveals that ...
... thousands of quails at a farm in Kimje.// It was ... a farm in Kimje, 262 kilometers southwest of Seoul to the ... in the farm of the latest outbreak. ,This recent ... starting with an first outbreak of highly virulent H5N1 virus on ...
... (Australia) government has decided //to toughen its laws on anti-smoking. ... carrying children. This comes in the wake of ... dies every 18 days, when exposed to cigarette smoke. ... Queenslanders Report, 2006, made these comments. ,A review ...
... University School of Medicine have found out that successful lung ... in many smokers. This study published in the December issue ... look at smoking relapse among people who were "forced" to ... found that close to half of 154 smokers who had ...
Cached Medicine News:Health News:Gene Discovered by Researchers Tied to Pancreatic Cancer 2Health News:A Basic Symptom Index For Early Detection Of Ovarian Cancer 2Health News:Lung Cancer Surgeries Doesn’t Help Breaking Nicotine Dependence in Smoker 2Health News:Lung Cancer Surgeries Doesn’t Help Breaking Nicotine Dependence in Smoker 3
... components that comprise the SmartPill GI ... comprise the SmartPill GI Monitoring System: ... Receiver software and SmartPill MotiliGI software. ... indispensable parts of the SmartPill GI ...
... for POLYGRAM NET™ (PNET) works with ... record and analyze pressure, swallow, and ... procedures. The PNET software and Polygraf ... water-perfused manometry catheters and the RespSponse™ ...
... Advanced pH Analysis for POLYGRAM NET™ ... Testing Application. Like the standard application, Advanced ... by either the Digitrapper™ Catheter-Based pH Recorder ... ,Designed primarily for use by clinical ...
Capillaries available in glass and "non-PVC" plastic. Match different analyzer requirements. Variety of sizes match sample-volume requirements of individual analyzers....
Medicine Products: